Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
40 hedge funds and large institutions have $5.87M invested in Unity Biotechnology in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 8 closing their positions.
209% more call options, than puts
Call options by funds: $71K | Put options by funds: $23K
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4.37% less ownership
Funds ownership: 25.71% → 21.34% (-4.4%)
5% less funds holding
Funds holding: 42 → 40 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
29% less capital invested
Capital invested by funds: $8.33M → $5.87M (-$2.46M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$119K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$77.9K |
| 3 |
Millennium Management
New York
|
+$42.1K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$31K |
| 5 |
Squarepoint
New York
|
+$24.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.33M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$210K |
| 3 |
Jane Street
New York
|
-$54.9K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$49.2K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$41.6K |
UBX Hedge Fund Activity: Q1 2024 in Review
40 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q1 2024, worth a combined $5.87M — down 29% from $8.33M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of UBX and 6 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, adding an estimated $119K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.33M sold.
- 40 institutional investors held Unity Biotechnology (UBX) as of Q1 2024, down from 42 in Q4 2023.
- Funds reported $5.87M of Unity Biotechnology stock for Q1 2024, down 29% quarter-over-quarter.
- 6 funds opened new Unity Biotechnology positions in Q1 2024 and 8 closed out, a net change of -2 holders.
- The largest Unity Biotechnology buyer in Q1 2024 was Renaissance Technologies, an estimated $119K added.
- The largest Unity Biotechnology seller in Q1 2024 was Armistice Capital, an estimated $1.33M sold.
Based on aggregated 13F filings for Q1 2024.